Overview
STRATA Q3 2025 revenue fell 21% yr/yr, missing analyst expectations
Net loss for Q3 2025 reduced to $1.6 mln from $2.1 mln yr/yr
Company's recurring revenue increased 3% yr/yr, equipment revenue fell 60%
Outlook
STRATA anticipates revenue growth from expanded CPT codes for reimbursement
STRATA plans to manage costs and expand patient pool through DTC efforts
Result Drivers
CPT CODE EXPANSION - Progress in expanding CPT codes for reimbursement expected to triple covered patient population in US
LITIGATION OUTCOME - Positive developments in lawsuit against LaserOptek, adding new defendants, improving chances for collecting damages
INTERNATIONAL MARKET SOFTNESS - Revenue decline attributed to instability in international trade policy
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $6.90 mln | $8.23 mln (2 Analysts) |
Q3 Net Income | -$1.60 mln | ||
Q3 Gross Profit | $4.20 mln | ||
Q3 Recurring Revenue | $5.50 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Strata Skin Sciences Inc is $8.00, about 79% above its November 12 closing price of $1.68
Press Release: ID:nGNX5RnWMr
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)